.After a handful of years in biotech, Mike Quigley, Ph.D., is going back to the pharma fold, occupying the best scientific research spot at Sanofi.Quigley will certainly start Sept. 30 as the French Big Pharma's main scientific officer and also worldwide head of research study, Sanofi told Intense Biotech in an emailed declaration.Quigley is actually switching out Frank Nestle, M.D., who left behind Sanofi this spring season amid a global overhaul of the firm's R&D unit. Nestle, who spent 8 years with the pharma, leapt over to Deerfield Control, where he currently serves as a companion on the therapies staff and also CEO of the firm's therapeutic exploration and also growth functions.
Quigley will certainly sign up with Sanofi from a San Francisco-based biotech that's in stealth, according to his LinkedIn account. He is actually presently noted as the company's founder, head of state and also chief executive officer.Given that August 2021, Quigley has actually acted as an endeavor partner at SV Wellness Investors, a medical care fund supervisor with current financial investments in biotechs like BioAge, Cerevance, Dualitas Therapies and Nimbus Therapies, and many more. Quigley in the past kept the best spot at Dualitas, a biotech that stays in secrecy, depending on to STAT.The soon-to-be Sanofi leader additionally recently helmed Therini Bio, an immunotherapy biotech functioning to establish procedures for neurodegenerative ailments steered through vascular problems.Prior to spending the final handful of years in biotech, Quigley has an even longer performance history in Major Pharma, most recently functioning as Gilead's elderly vice president of investigation the field of biology up until the summertime of 2021. Just before that, he appeared more than four years across different management roles at Bristol Myers Squibb and also acted as a medical director at Johnson & Johnson's Janssen upper arm before that.Sanofi mentioned Quigley's purpose in his new duty would be actually to "optimize our chance of results with ideal partnerships across our institution as well as beyond, bringing best-in-class advancement as well as cultivating as well as sourcing new industry-leading skill along with a dedication to diversity," depending on to an inner memo gotten through STAT.